human, recombinant, E. coli
For in vitro use only!
Shipping: shipped at ambient temperature
Storage Conditions: store at -20 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Molecular Weight: 13 kDa
Accession number: P40933
Accession number: P40933
Purity: > 95 % (SDS-PAGE, RP-HPLC)
Form: lyophilised (IL-15 was lyophilised from a 1 mg/ml solution with 5 mM Tris-HCL pH 8.0)
Solubility: It is recommended to reconstitute the lyophilised IL-15 in bidest H2O not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA)
Activity: ED50: < 0.5 ng/ml, corresponding to a specific activity 2 x 106 IU/mg, determined by the dosedependent stimulation of the proliferation of CTLL-2 cells.
Interleukin (IL)-15 is a pleiotropic pro-inflammatory cytokine that is expressed in several inflammatory disorders, including rheumatoid arthritis, psoriasis, and pulmonary inflammatory diseases. IL-15 promotes activation of T-cells, neutrophils, and macrophages, and is critical to dendritic cell function in several model systems. Recent emerging data suggest that IL-15 may serve as a useful therapeutic target across a range of disease states. Advances in the past year highlight the beneficial effect of IL-15 neutralisation in models of psoriasis and diabetes. Further evidence for IL-15 expression and effector function has emerged across a range of rheumatic disorders, including juvenile inflammatory arthritis, rheumatoid arthritis, and Kawasaki disease. Interleukin-15 (IL-15) is a gammacommon cytokine, which plays an important role in the development, survival, and proliferation of NK, NK Tand CD8+ T-cells. Recombinant human IL-15 produced in E. coli is a single, non-glycosylated polypeptide chain containing 114 amino acids and having a molecular mass of 13 kDa. IL-15 is purified by proprietary chromatographic techniques.
D'Agostino et al. (2004) Interleukin-15, as interferon-gamma, induces the killing of Leishmania infantum in phorbol-myristateacetate- activated macrophages increasing interleukin-12. Scand. J. Immunol. 60:609.
Roychowdhury et al. (2004) Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res. 64:8062.
Lieberman et al. (2004) Interleukin-15-deficient mice develop protective immunity to Toxoplasma gondii. Infect. Immun. 72:6729.
Millington et al. (2004) Interleukin-15 is not required for the induction or maintenance of orally induced peripheral tolerance. Immunology. 113:304.
Ge et al. (2004) Synthesis and secretion of interleukin-15 by freshly isolated human bronchial epithelial cells. Int. Arch. Allergy Immunol. 135:235.
Grzegorzewska et al. (2004) Serum levels of cancer antigen 125 and interleukin-15 in relation to the nutrition status of peritoneal dialysis patients. Adv. Perit. Dial. 20:185.